New CAR t cell therapy targets tough childhood cancers in early trial

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been modified to recognize and attack a marker called B7-H3 on cancer cells. The study also uses chemotherapy drugs fludarabine and cyclophosphamide to prepare the body for the cell infusion.